-+ 0.00%
-+ 0.00%
-+ 0.00%

ABL Diagnostics wins court nod to take over Texcell assets and operations for EUR 225,000

PUBT·07/23/2026 07:22:50
Listen to the news
ABL Diagnostics wins court nod to take over Texcell assets and operations for EUR 225,000
  • ABL Diagnostics was selected to take over TEXCELL’s assets and operations, adding viral safety and biosafety capabilities to its molecular diagnostics platform.
  • Economic value of the deal totals about EUR 2.9 million, including EUR 225,000 for assets and EUR 30,000 for inventory.
  • The package includes about EUR 531,792.74 of equipment lease commitments, about EUR 930,000 of planned industrial and technology investment, and EUR 1 million of added working capital.
  • Operations will continue at the Genopole site in Evry-Courcouronnes, with 29 staff transferring; about five additional hires are planned.
  • TEXCELL generated about EUR 5.4 million revenue in 2024, down from EUR 6.2 million in 2023 and EUR 7.5 million in 2022.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260723585284) on July 23, 2026, and is solely responsible for the information contained therein.